Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest

Affimed (NASDAQ:AFMD) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 846,900 shares, an increase of 38.5% from the November 30th total of 611,400 shares. Based on an average daily trading volume, of 253,700 shares, the short-interest ratio is currently 3.3 days. Approximately 6.5% of the shares of the stock are short sold.

Affimed Stock Performance

NASDAQ AFMD opened at $1.29 on Friday. The business’s 50 day moving average price is $2.76 and its 200-day moving average price is $3.91. Affimed has a fifty-two week low of $1.14 and a fifty-two week high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Wall Street Analyst Weigh In

AFMD has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Wells Fargo & Company decreased their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, Stifel Nicolaus dropped their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, November 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Affimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Institutional Investors Weigh In On Affimed

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Affimed during the 3rd quarter worth about $44,000. Choreo LLC bought a new stake in Affimed in the second quarter worth about $54,000. FMR LLC boosted its position in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC grew its stake in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.